Testing BTV100 for moderate to severe dry eye
Part of Eyes & vision clinical trials.
This trial tests BTV100, an investigational eye drop, for people with ongoing moderate to severe dry eye disease. It aims to see if the treatment can improve dryness and discomfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had dry eye symptoms for at least 6 months.
- You are willing to not wear contact lenses during the study.
- You have not used Restasis, Cequa, or similar eye drops in the last 28 days.
- Your best corrected vision is 20/100 or better in both eyes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an eye drop called OT202 for people with moderate to severe dry eye. It aims to see if it can help reduce dryness and improve eye comfort.
This study tests whether RCI001, a new eye drop treatment, can help people with dry eye disease. If you've had dry eye symptoms for at least 6 months and are interested in trying a new treatment, this trial may be for you.
This study tests a new eye drop (PRO-190) against a common artificial tear (Systane Ultra) to see how safe and comfortable it is. Healthy volunteers will use the drops and be monitored for any side effects or changes in their eyes.
This trial compares two different dry-eye eye drops to see which works better and is safe. You may be able to join if you’ve had dry eye for at least 3 months and meet specific eye-test results.
This trial studies whether BUFY01 eye drops work better than SVS20 for treating dry eye disease. You may be able to join if you have dry eye symptoms for at least 3 months and meet eye exam score and tear-test requirements.
This study tests new eye drops for people with mild to moderate dry eye disease. It will check how well the drops work and if they are safe over time.
Hear when a new Dry Eye trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.